Premium
Preoperative vitrectomy treatment preventing vitreous haemorrhage
Author(s) -
HALFELD FURTADO DE MENDONCA R,
FERREIRA EL,
ARAúJO FERRAZ D,
DE OLIVEIRA MAIA JUNIOR O,
YUKIHIKO TAKAHASHI W
Publication year - 2012
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2012.s039.x
Subject(s) - medicine , vitrectomy , bevacizumab , triamcinolone acetonide , incidence (geometry) , diabetic retinopathy , vitreous hemorrhage , ophthalmology , visual acuity , adverse effect , surgery , endophthalmitis , diabetes mellitus , chemotherapy , physics , optics , endocrinology
Purpose To compare the results of preoperative intravitreal bevacizumab (IVB) and triamcinolone (IVT) treatment as prevention of early postvitrectomy haemorrhage in proliferative diabetic retinopathy (PDR). Methods 27 eyes with PDR were distributed in 3 groups (9 patients each): the IVB group received 1.25 mg bevacizumab, the IVT group received 4,0mg triamcinolone and the control group underwent a sham procedure. The incidence of early postvitrectomy hemorrhage, best corrected visual acuity (BCVA) and adverse events were considered. Results The lowest incidence of vitreous hemorrhage was in IVB group but not statistically significant. The rate of bleeding immediately after surgery was higher in IVT group. Considering VA, in the IVT group the improvement was statistically significant (p ≤ 0.001). Conclusion Intravitreal injection of bevacizumab 1 week before vitrectomy seems to reduce the incidence of early postvitrectomy haemorrhage in diabetic patients. There was a better VA outcome in the triamcinolone group.